The value of a German life science company hinges on its patent portfolio, particularly for targeting the major markets of US and Europe. Differences in legal requirements between the US and Europe can be critical. Acceptable patent practice in Europe can be fatal in the US, and vice versa. The legal requirements in the US and Europe continue to evolve, bringing new opportunities and pitfalls. Dealmakers must be aware of the key issues affecting the development and valuation of a patent portfolio. Panelists will discuss and contrast the key issues relevant for German life science companies.
Continuation and divisional practice in US and Europe
Claiming methods of treatment in Europe
Filing decisions given available test data
US pitfalls: Best mode requirement and inequitable conduct
Filing PCT applications in English to accelerate US prior art status
US Patent Term Adjustment post-Wyeth
Impact of Biosimilar legislation as part of U.S. Health Care Reform
Implications of Bilski, Prometheus and Myriad decisions and comparison with the current law in Europe
Speakers:
Dr. Rouget F. (“Ric”) Henschel (U.S. Patent Attorney, member of Virginia and District of Columbia Bars), Foley & Lardner
Dr. Fritz Lahrtz (German and European Patent and Trademark Attorney), Isenbruck
Related Insights
July 7, 2025
Labor & Employment Law Perspectives
Florida Bucks Trend, Enacts New Employer-Friendly Noncompete Statute
While the recent trend across the country has been to restrict noncompete agreements, Florida has just made it easier for employers to…
July 7, 2025
Health Care Law Today
DOJ-HHS False Claims Act Working Group: Focus on Medicare Payment Suspensions
In a July 2, 2025, press release, the U.S. Department of Justice (DOJ) announced a new “DOJ-HHS False Claims Act Working Group” (the…
July 2, 2025
Energy Current
Has SCOTUS Pre-decided Whether the NRC Can License Private Off-Site High-Level Nuclear Waste Storage Facilities?
On June 18, 2025, the U.S. Supreme Court, in NRC v. Texas, issued an opinion holding that the State of Texas did not have standing to…